Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherChemotherapy, Antibiotics, and Gene Therapy

Disruption of ovarian cancer STAT3 and p38 signaling with a small molecule inhibitor of PTP4A3 phosphatase

John S. Lazo, Kelly N. Isbell, Sai Ashish Vasa, Danielle C. Llaneza, Ettore J. Rastelli, Peter Wipf and Elizabeth R. Sharlow
Journal of Pharmacology and Experimental Therapeutics January 10, 2023, JPET-AR-2022-001401; DOI: https://doi.org/10.1124/jpet.122.001401
John S. Lazo
1Pharmacology, University of Virginia, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John S. Lazo
  • For correspondence: lazo@virginia.edu
Kelly N. Isbell
2Biology, KeViRx, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai Ashish Vasa
2Biology, KeViRx, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle C. Llaneza
1Pharmacology, University of Virginia, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ettore J. Rastelli
3Chemistry, University of Pittsburgh, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Wipf
4Pittsburgh, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth R. Sharlow
1Pharmacology, University of Virginia, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

JPET-AR-2022-001401
DOI 
https://doi.org/10.1124/jpet.122.001401
PubMed 
36627205

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Published online January 10, 2023.

Article Versions

  • You are currently viewing an Earlier version of this article (January 10, 2023 - 13:16).
  • earlier version (February 21, 2023 - 05:25).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. John S. Lazo1,*,
  2. Kelly N. Isbell2,
  3. Sai Ashish Vasa2,
  4. Danielle C. Llaneza1,
  5. Ettore J. Rastelli3,
  6. Peter Wipf4, and
  7. Elizabeth R. Sharlow1
  1. 1Pharmacology, University of Virginia, United States
  2. 2Biology, KeViRx, Inc., United States
  3. 3Chemistry, University of Pittsburgh, United States
  4. 4Pittsburgh, United States
  1. ↵* Corresponding Author:
    John S. Lazo, Pharmacology, University of Virginia, P.O. Box 800735, 409 Lane Road, Charlottesville, Virginia, 22908-0735, United States. E-mail: lazo{at}virginia.edu

Statistics from Altmetric.com

Article usage

Article usage: January 2023 to March 2023

AbstractFullPdf
Jan 2023197097
Feb 20232921281
Mar 20233451941

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 1
1 Apr 2023
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Disruption of ovarian cancer STAT3 and p38 signaling with a small molecule inhibitor of PTP4A3 phosphatase
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherChemotherapy, Antibiotics, and Gene Therapy

PTP4A3 and ovarian cancer

John S. Lazo, Kelly N. Isbell, Sai Ashish Vasa, Danielle C. Llaneza, Ettore J. Rastelli, Peter Wipf and Elizabeth R. Sharlow
Journal of Pharmacology and Experimental Therapeutics January 10, 2023, JPET-AR-2022-001401; DOI: https://doi.org/10.1124/jpet.122.001401

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherChemotherapy, Antibiotics, and Gene Therapy

PTP4A3 and ovarian cancer

John S. Lazo, Kelly N. Isbell, Sai Ashish Vasa, Danielle C. Llaneza, Ettore J. Rastelli, Peter Wipf and Elizabeth R. Sharlow
Journal of Pharmacology and Experimental Therapeutics January 10, 2023, JPET-AR-2022-001401; DOI: https://doi.org/10.1124/jpet.122.001401
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Targeting LGR5-positive cells in ovarian cancer
  • Ocular Palonosetron for Prevention of Nausea and Vomiting
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics